Current Infectious Disease Reports

, Volume 8, Issue 1, pp 35–42 | Cite as

Malaria: Diagnosis and treatment of falciparum malaria in travelers during and after travel



Plasmodium falciparum is responsible for most of the mortality in travelers related to imported malaria. Problems that occur during travel include the inaccuracy of a microscopic diagnosis of malaria, both false positives and false negatives, when ill travelers seek care while abroad. A false positive diagnosis can result in unnecessary parenteral injections that carry a risk of transmission of blood-borne pathogens, receipt of potentially dangerous drugs such as halofantrine, or receipt of fake, counterfeit drugs. Increased morbidity and mortality are associated with delays in diagnosis and initiation of prompt treatment for falciparum malaria. Availability of expert microscopy to confirm the diagnosis of malaria is limited. The presence of splenomegaly and thrombocytopenia are strongly associated with malaria and would justify empiric treatment. The availability of atovaquone-proguanil, a safe and well tolerated oral drug, should prompt a reconsideration of current treatment recommendations that discourage empiric treatment on clinical suspicion alone.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Eliades MJ, Shah S, Nguyen-Dinh P, et al.: Malaria surveillance-United States, 2003. MMWR Surveill Summ 2005, 54:25–40.PubMedGoogle Scholar
  2. 2.
    Newman RD, Parise ME, Barber AM, Steketee RW: Malariarelated deaths among U.S. travelers, 1963–2001. Ann Intern Med 2004, 141:547–555. Review of the 185 deaths due to malaria reported to the National Malaria Surveillance System between 1961 and 2001. Very useful discussions of risk factors and clinical management decisions contributing to preventable deaths and current status of intravenous quinidine, the only drug available in the United States to treat severe and complicated malaria.PubMedGoogle Scholar
  3. 3.
    Greenberg AE, Lobel HO: Mortality from Plasmodium falciparum malaria in travelers from the United States, 1959 to 1987. Ann Intern Med 1990, 113:326–327.PubMedGoogle Scholar
  4. 4.
    Muhlberger N, Jelinek T, Gascon J, et al.: Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J 2004, 3:5.PubMedCrossRefGoogle Scholar
  5. 5.
    Elliott JH, O’Brien D, Leder K, et al.: Imported Plasmodium vivax malaria: demographic and clinical features in nonimmune travelers. J Travel Med 2004, 11:213–217.PubMedCrossRefGoogle Scholar
  6. 6.
    Leder K, Black J, O’Brien D, et al.: Malaria in travelers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2004, 39:1104–1112.PubMedCrossRefGoogle Scholar
  7. 7.
    Jelinek T, Schulte C, Behrens R, et al.: Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis 2002, 34:572–576.PubMedCrossRefGoogle Scholar
  8. 8.
    De Monbrison F, Gerome P, Chaulet JF, et al.: Comparative diagnostic performance of two commercial rapid tests for malaria in a non-endemic area. Eur J Clin Microbiol Infect Dis 2004, 23:784–786.PubMedCrossRefGoogle Scholar
  9. 9.
    Farcas GA, Zhong KJ, Lovegrove FE, et al.: Evaluation of the Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am J Trop Med Hyg 2003, 69:589–592.PubMedGoogle Scholar
  10. 10.
    Wongsrichanalai C, Arevalo I, Laoboonchai A, et al.: Rapid diagnostic devices for malaria: field evaluation of a new prototype immunochromatographic assay for the detection of Plasmodium falciparum and non-falciparum Plasmodium. Am J Trop Med Hyg 2003, 69:26–30.PubMedGoogle Scholar
  11. 11.
    Whitty CJM, Armstrong M, Behrens RH: Self-testing for falciparum malaria with antigen-capture cards by travelers with symptoms of malaria. Am J Trop Med Hyg 2000, 63:295–297.PubMedGoogle Scholar
  12. 12.
    Behrens RH, Whitty CJ: Self-use of rapid tests for malaria diagnosis. Lancet 2000, 355:237.PubMedCrossRefGoogle Scholar
  13. 13.
    Jelinek T, Grobusch MP, Nothdurft HD: Use of dipstick tests for the rapid diagnosis of malaria in nonimmune travelers. J Travel Med 2000, 7:175–179.PubMedCrossRefGoogle Scholar
  14. 14.
    Jelinek T, Amsler L, Grobusch MP, Nothdurft HD: Self-use of rapid tests for malaria diagnosis by tourists. Lancet 1999, 354:1609.PubMedCrossRefGoogle Scholar
  15. 15.
    Trachsler M, Schlagenhauf P, Steffen R: Feasibility of a rapid dipstick antigen-capture assay for self-testing of travelers’ malaria. Trop Med Int Health 1999, 4:442–447.PubMedCrossRefGoogle Scholar
  16. 16.
    Marx A, Pewsner D, Egger M, et al.: Meta-analysis: accuracy of rapid tests for malaria in travelers returning from endemic areas. Ann Intern Med 2005, 142:836–846.PubMedGoogle Scholar
  17. 17.
    Reyburn H, Mbatia R, Drakeley C, et al.: Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004, 329:1212. Importance to travelers was the performance of microscopy for the diagnosis of malaria in over 4000 cases. Accuracy was 66%, false positive rate was 39% and false negative rate was 27%.PubMedCrossRefGoogle Scholar
  18. 18.
    Causer LM, Filler S, Wilson M, et al.: Evaluation of reported malaria chemoprophylactic failure among travelers in a US University Exchange Program, 2002. Clin Infect Dis 2004, 39:1583–1588. An investigation of a cluster of “chemoprophylaxis failures” that occurred in a cultural exchange group visiting Ghana. Falsely positive microscopic diagnoses in Ghana led to inappropriate and unnecessary treatments including parenteral injections.PubMedCrossRefGoogle Scholar
  19. 19.
    Centers for Disease Control and Prevention: Sudden death in a traveler following halofantrine administration —Togo, 2000. MMWR Morb Mortal Wkly Rep 2001, 50:169–170, 179.Google Scholar
  20. 20.
    Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf 2004, 27:25–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al.:Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther 2005, 30:285–290.PubMedCrossRefGoogle Scholar
  22. 22.
    Ray WA, Murray KT, Meredith S, et al.: Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004, 351:1089–1096.PubMedCrossRefGoogle Scholar
  23. 23.
    Jaspers CA, Hopperus Buma AP, van Thiel PP, et al.: Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996, 55:230–234.PubMedGoogle Scholar
  24. 24.
    Davis TM, Dembo LG, Kaye-Eddie SA, et al.: Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996, 42:415–421.PubMedCrossRefGoogle Scholar
  25. 25.
    Dondorp AM, Newton PN, Mayxay M, et al.: Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004, 9:1241–1246.PubMedCrossRefGoogle Scholar
  26. 26.
    Basco LK: Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 2004, 70:245–250.PubMedGoogle Scholar
  27. 27.
    Antinori S, Galimberti L, Gianelli E, et al.: Prospective observational study of fever in hospitalized returning travelers and migrants from tropical areas, 1997–2001. J Travel Med 2004, 11:135–142.PubMedCrossRefGoogle Scholar
  28. 28.
    Casalino E, Le Bras J, Chaussin F, et al.: Predictive factors of malaria in travelers to areas where malaria is endemic. Arch Intern Med 2002, 162:1625–1630.PubMedCrossRefGoogle Scholar
  29. 29.
    Doherty JF, Grant AD, Bryceson AD: Fever as the presenting complaint of travellers returning from the tropics. QJM 1995, 88:277–281.PubMedGoogle Scholar
  30. 30.
    MacLean J, Lalonde R, Ward B: Fever from the tropics. Travel Medicine Advisor 1994, 5:27.2–27.4.Google Scholar
  31. 31.
    O’Brien D, Tobin S, Brown GV, Torresi J: Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001, 33:603–609.PubMedCrossRefGoogle Scholar
  32. 32.
    West NS, Riordan FA: Fever in returned travellers: a prospective review of hospital admissions for a 2(1/2) year period. Arch Dis Child 2003, 88:432–434.PubMedCrossRefGoogle Scholar
  33. 33.
    D’Acremont V, Ambresin AE, Burnand B, Genton B: Practice guidelines for evaluation of Fever in returning travelers and migrants. J Travel Med 2003, 10(Suppl2):S25–52. Clinically useful algorithms based on expert opinion and a systematic review of the published literature for the evaluation of fever in returning travelers.PubMedGoogle Scholar
  34. 34.
    Day JH, Behrens RH: Delay in onset of malaria with mefloquine prophylaxis. Lancet 1995, 345:398.PubMedCrossRefGoogle Scholar
  35. 35.
    Lewis SJ, Davidson RN, Ross EJ, Hall AP: Severity of imported falciparum malaria: effect of taking antimalarial prophylaxis. BMJ 1992, 305:741–743.PubMedCrossRefGoogle Scholar
  36. 36.
    Reyburn H, Behrens RH, Warhurst D, Bradley D: The effect of chemoprophylaxis on the timing of onset of falciparum malaria. Trop Med Int Health 1998, 3:281–285.PubMedCrossRefGoogle Scholar
  37. 37.
    Stuiver PC, van Rijswijk JB, Visser LG: Delayed onset of malignant tertian malaria through the inappropriate use of doxycycline: another threat to patients returning from malarious areas. J Travel Med 1996, 3:193.CrossRefPubMedGoogle Scholar
  38. 38.
    Wetsteyn JC, de Geus A: Chloroquine-resistant falciparum malaria imported into the Netherlands. Bull World Health Organ 1985, 63:101–108.PubMedGoogle Scholar
  39. 39.
    Angell SY, Behrens RH: Risk assessment and disease prevention in travelers visiting friends and relatives. Infect Dis Clin North Am 2005, 19:49–65.PubMedCrossRefGoogle Scholar
  40. 40.
    Bacaner N, Stauffer B, Boulware DR, et al.: Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004, 291:2856–2864.PubMedCrossRefGoogle Scholar
  41. 41.
    Loutan L: Malaria: still a threat to travelers. Int J Antimicrob Agents 2003, 21:158–163.PubMedCrossRefGoogle Scholar
  42. 42.
    Bouchaud O, Cot M, Kony S, et al.: Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg 2005, 72:21–25.PubMedGoogle Scholar
  43. 43.
    Bunn A, Escombe R, Armstrong M, et al.: Falciparum malaria in malaria-naive travelers and African visitors. QJM 2004, 97:645–649.PubMedCrossRefGoogle Scholar
  44. 44.
    D’Acremont V, Landry P, Mueller I, et al.: Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg 2002, 66:481–486. A prospective study identifying inadequate chemoprophylaxis, sweating, splenomegaly, thrombocytopenia, and the absence of abdominal pain, leucocytosis, and eosinophilia as predictors of parasitemia. Rapid assessments based on clinical and standard laboratory findings facilitate oral empiric treatment for those at higher risk of falciparum malaria.Google Scholar
  45. 45.
    Robinson P, Jenney AW, Tachado M, et al.: Imported malaria treated in Melbourne, Australia: epidemiology and clinical features in 246 patients. J Travel Med 2001, 8:76–81.PubMedCrossRefGoogle Scholar
  46. 46.
    Hanscheid T, Melo-Cristino J, Grobusch MP, Pinto BG:Avoiding misdiagnosis of imported malaria: screening of emergency department samples with thrombocytopenia detects clinically unsuspected cases. J Travel Med 2003, 10:155–159.PubMedCrossRefGoogle Scholar
  47. 47.
    Patel U, Gandhi G, Friedman S, Niranjan S: Thrombocytopenia in malaria. J Natl Med Assoc 2004, 96:1212–1214.PubMedGoogle Scholar
  48. 48.
    Kockaerts Y, Vanhees S, Knockaert DC, et al.: Imported malaria in the 1990s: a review of 101 patients. Eur J Emerg Med 2001, 8:287–290.PubMedCrossRefGoogle Scholar
  49. 49.
    Badiaga S, Barrau K, Parola P, et al.: Contribution of nonspecific laboratory test to the diagnosis of malaria in febrile travelers returning from endemic areas: value of hypocholesterolemia. J Travel Med 2002, 9:117–121.PubMedCrossRefGoogle Scholar
  50. 50.
    2004 Canadian recommendations for the prevention and treatment of malaria among international travelers. Can Commun Dis Rep 2004, 30(Suppl 1):1–62.Google Scholar
  51. 51.
    Bradley DJ, Bannister B: Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health 2003, 6:180–199.PubMedGoogle Scholar
  52. 52.
    Treatment of Malaria (Guidelines for Clinicians). http:// htm. Assessed November 9, 2005. A website providing treatment guidelines and tables of drugs with dosing recommendations for adults and children currently used to treat malaria in the United States.Google Scholar
  53. 53.
    ter Kuile FO, Nosten F, Luxemburger C, et al.: Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 1995, 73:631–642.PubMedGoogle Scholar
  54. 54.
    Rendi-Wagner P, Noedl H, Wernsdorfer WH, et al.:Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 2002, 81:167–173.PubMedCrossRefGoogle Scholar
  55. 55.
    Treatment of severe Plasmodium falciparum malaria with quinidine gluconate: discontinuation of parenteral quinine from CDC drug service. MMWR Morb Mortal Wkly Rep 1991, 40:240.Google Scholar
  56. 56.
    Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC Drug Service. MMWR Recomm Rep 1991, 40:21–23.Google Scholar
  57. 57.
    Weber G, Schwartz E, Schlaeffer F, et al.: Imported severe falciparum malaria in Israel. J Travel Med 1998, 5:97–99.PubMedCrossRefGoogle Scholar
  58. 58.
    Humar A, Sharma S, Zoutman D, Kain KC: Fatal falciparum malaria in Canadian travelers. CMAJ 1997, 156:1165–1167.PubMedGoogle Scholar
  59. 59.
    Rosenthal PJ, Petersen C, Geertsma FR, Kohl S: Availability of intravenous quinidine for falciparum malaria. N Engl J Med 1996, 335:138.PubMedCrossRefGoogle Scholar
  60. 60.
    Availability of parenteral quinidine gluconate for treatment of severe or complicated malaria. MMWR Morb Mortal Wkly Rep 1996, 45:494–495.Google Scholar
  61. 61.
    Availability and use of parenteral quinidine gluconate for severe or complicated malaria. MMWR Morb Mortal Wkly Rep 2000, 49:1138–1140.Google Scholar
  62. 62.
    Dondorp N, Nosten F, Stepniewska K, et al.: Artesunate versus quinine for treatment of severe falciparum malaria: a randomized trial. Lancet 2005, 366:717–725. A randomized, controlled clinical trial demonstrating a 35% decrease in mortality with intravenous artesunate when compared to intravenous quinine for the treatment of severe and complicated falciparum malaria.PubMedCrossRefGoogle Scholar
  63. 63.
    Magill A, Panosian C: Making antimalarial agents available in the United States. N Engl J Med 2005, 353:335–337.PubMedCrossRefGoogle Scholar
  64. 64.
    Bruneel F, Hocqueloux L, Alberti C, et al.: The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003, 167:684–689. Shock, pulmonary edema, metabolic acidosis, and coagulation disorders were the main predictors of death in this single center experience with 188 cases of severe imported falciparum malaria in travelers. Of the 10 patients who died, none had taken any chemoprophylaxis drugs showing that even taking drugs incorrectly or using inappropriate drugs can still help prevent death.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Experimental TherapeuticsWalter Reed Army Instituteof ResearchSilver SpringUSA

Personalised recommendations